MedTrace Logo

Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain

NCT01049373 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 221

Last updated 2012-09-06

Study results available
· View outcomes & findings →

Summary

To evaluate superiority of HDC in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.

Conditions

  • Low Back Pain

Interventions

DRUG

HDC

(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.

DRUG

Placebo solution

10 drops, t.i.d, 15 weeks

Sponsors & Collaborators

  • Pascoe Pharmazeutische Praeparate GmbH

    lead INDUSTRY

Principal Investigators

  • Andre M Beer, MD, PhD · Department of True Naturopathy, Blankenstein Hospital; Im Vogelsang 5-11; D-45527 Hattingen; Germany;

  • Juergen Kraemer, Prof · St. Josef Hospital. Gudrunstr. 56, 44791 Bochum, Germany

  • Anja Braschoss, MD · Pascoe Pharmazeutische Praeparate GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049373 on ClinicalTrials.gov